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Abstract
Angiotensin-Converting Enzyme (ACE2) is a transmembrane enzyme
located in cells in various tissues around the body. Its normal role is the
conversion of Angiotensin II to Angiotensin 1-7 leading to vasodilation and
a subsequent reduction in blood pressure via the
renin-angiotensin-aldosterone system. ACE2 also plays a pivotal role in the
infection of COVID-19 as it determines entry of virus into human cells.
SARS-CoV-2 uses one of its four structural proteins, the spike (S)
glycoprotein, to bind to the ACE2 receptor. This entry into the cell begins
the process of infection and spread of the disease; because of the
abundance of ACE2 throughout the body, coronaviruses can enter several
different organs. This multi-cell-entry via ACE2 is why COVID-19 affects
multiple organ systems in the human body. Currently, therapies targeting
ACE2 expression are limited. MicroRNA (miRNA)s are short non-coding
RNA that downregulate the expression of a variety of proteins, and
therefore offer a mechanism by which to inhibit the expression of ACE2.
MiRNAs can potentially downregulate ACE2 protein synthesis by binding
to the mRNA of ACE2 at a seed sequence. This binding results in mRNA
degradation or inhibition of translation. Thus, our goal was to identify
miRNA that may potentially target and downregulate ACE2. TargetScan,
DIANA-MicroT, and PicTar are three algorithms that predict miRNAs that
can bind to the mRNA of ACE2 and downregulate its expression.
Together, the prediction tools resulted in 57 shared human miRNAs that
target ACE2. We then utilized self-defined parameters to narrow down our
list and identified hsa-miR-4520-2-3p as our predicted miRNA to target
ACE2. This miRNA will be experimentally verified in the future.

Introduction

Conclusion
Based on our in silico methodology, hsa-miR-4520-2-3p was narrowed as a
potential miRNA targeting ACE2. This finding was based on a complete literature
review, production of a list of miRNAs that target ACE2 by the three algorithms
TargetScan, DIANA-MicroT, and PicTar, and self-defined parameters that further
narrowed down the list of miRNAs predicted to target ACE2.
A)

Figure 2. SARS-CoV-2 has a diameter of 150 nanometers and is made up of four structural
proteins. One of those four proteins, the spike (S) glycoprotein on SARS-CoV-2 binds to the
ACE2 protein. The virus then enters the cell via endocytosis. This image is from the CDC.

The main role of ACE2 is the conversion of Angiotensin II to Angiotensin 1-7,
which opposes the actions of Angiotensin II. Angiotensin II is a peptide hormone
that causes vasoconstriction, increased blood pressure, and sodium retention.
Angiotensin 1-7 is a peptide, with one less amino acid than Angiotensin II, that
causes vasodilation and decreased blood pressure. Thus, the normal function of
ACE2 is important to maintain homeostasis in the human body. ACE2 is prevalent
in many tissues throughout the body, including the lungs, esophagus, stratified
epithelial cells, parts of the large intestine, and the brain; in fact ACE2 is capable
or reducing levels of β-amyloid (Aβ) – a protein involved in the pathogenesis of
Alzheimer’s disease (AD). The expression of ACE2 throughout the body is what
can lead to multi-tissue infection when binding with SARS-CoV-2.
MicroRNAs (miRNA) offer a novel approach for ACE2 inhibition. MiRNAs are
~22 nucleotide, single-stranded, non-coding RNAs that regulate gene expression
by binding to the messenger RNA (mRNA) of a protein at the miRNA seed
sequence (Agarwal 2015). A seed sequence is a region of 2-8 nucleotides on the
miRNA that is complementary to the within the 3’ untranslated region (UTR)
within the mRNA. After miRNA binds to mRNA, the RNA-induced silencing
complex (RISC) interferes with translation of ACE2 mRNA, resulting in either
mRNA degradation or inhibition of ACE2 translation. Interference of translation
allows miRNAs to downregulate ACE2 protein expression in order to decrease the
number of opportunities available for the virus to infect a cell.

B)
Table 1. Above is a table showing a list of 20 miRNAs (narrowed down from the original 57) that
are predicted to target ACE2. The miRNAs are ranked from the highest context++ score percentile to
lowest. The table shows the specific scores assigned to these miRNA from TargetScan,
DIANA-MicroT, and PicTar, yellow, blue, and orange, respectively.

Figure 5. A) SARS-CoV-2 utilizes S-protein binding to ACE2 protein to facilitate entry into the
cell in absence of miRNA. B) Presence of miRNA eliminates ACE2, preventing SARS-CoV-2
from gaining entry into the cell.

However, finding a miRNA that can suppress ACE2 is quite difficult. This is due to
the reason that each miRNA is not exclusively bound to a specific mRNA. Thus,
while the results were consistent with each other and allowed for the finding of one
miRNA that could potentially target ACE2 in an experimental setting,
hsa-miR-4520-2-3p could be a false positive when experimentally tested.

Figure 4. Filtered list of miRNA that potentially target ACE2. If there was experimental
evidence on PubMed relating that a miRNA downregulated ACE2, then that miRNA was
confirmed. If there were articles about ACE2 linked to the miRNA but no direct relationship,
then that miRNA was unconfirmed.

Other limitations within this research were:
• The algorithms used limited results of the study, resulting in the possibility of
both Type I and Type II errors.
• The parameters defined by the researchers within this experiment were limiting
• The composition of miRNA has a short target sequence, hindering easy
transfection of miRNA into cells for treatment of SARS-CoV-2

Future Research
Materials & Methods

MiRNA Finalized by Parameters and Ranked by miTG Score

Experimental research with the determined hsa-miR-4520-2-3p in order to
determine if the miRNA does indeed target ACE2. Results of this future experiment
could support or eliminate this miRNA as a potential regulator of ACE2.
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fever, cough, myalgia, shortness of breath, hypoxemia, and acute respiratory distress
syndrome. However, people who are positive for COVID-19 may also be
asymptomatic, which makes viral spread more effective. Incubation period of
SARS-CoV-2 is between 2-14 days.
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Figure 3. Workflow for research project.

Results
Separately, TargetScan, DIANA-MicroT, and PicTar algorithms resulted in 281, 60,
and one miRNA(s) predicted to target the ACE2 protein, respectively. 57 miRNAs
were shared across the algorithms as potential targets for ACE2. 56 of the predicted
miRNAs were shared among TargetScan and DIANA-MicroT, and one miRNA,
miR-200c-3p was shared among all 3 algorithms.

Table 2. List of 20 miRNAs (narrowed down from the original 57) that are predicted to target
ACE2. The varying shades of red indicate when a group of miRNAs are eliminated from being the
sole miRNA (determined by the self-defined parameters) to target ACE2. The darkest red indicates
the first level of elimination, while the lightest red indicates the last level of elimination. The
miRNAs are ranked from the highest miTG score to the lowest across each group. The miRNA
highlighted in green is the determined miRNA that targets ACE2.
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